1 [미국특허] Chimeric Flavivirus Lyssavirus Vaccines 미국(US) | 공개 | 출원인 : Dallmeier, Kai; | 출원번호 : 17273985 ( 2019-09-06 ) | 공개번호 : 20210353735 (2021-11-18) | IPC : A61K-039/12(2006.01); C12N-007/00(2006.01); C12N-015/85(2006.01) The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region. 대표청구항 원문보기 초록 연관자료탐색 The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region. 2 [국제특허] NOVEL LYSSAVIRUS PHOSPHOPROTEINS 국제(WO) | 공개 | 출원인 : THE UNIVERSITY OF MELBOURNE; | 출원번호 : AU2019/050908 ( 2019-08-27 ) | 공개번호 : 2020/198776 (2020-10-08) | IPC : C12N-007/01(2006.01); C12N-007/04(2006.01); A61K-039/205(2006.01); C07K-014/145(2006.01) The present invention provides an isolated lyssavirus phosphoprotein (P-protein) comprising one or more amino acid substitutions in a signal transducer and activator of transcription 1 (STAT1) interacting surface of the P-protein. 원문보기 초록 연관자료탐색 The present invention provides an isolated lyssavirus phosphoprotein (P-protein) comprising one or more amino acid substitutions in a signal transducer and activator of transcription 1 (STAT1) interacting surface of the P-protein. 3 [미국특허] Lyssavirus antigen constructs 미국(US) | 등록 | 출원인 : GLAXOSMITHKLINE BIOLOGICALS SA; | 출원번호 : 16630951 ( 2018-07-16 ) | 특허번호 : 11278613 (2022-03-22) | 등록번호 : 11278613 (2022-03-22) | IPC : A61K-039/205(2006.01); A61K-009/127(2006.01); A61K-039/00(2006.01) Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity. 대표청구항 원문보기 초록 연관자료탐색 Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity. 4 [국제특허] CHIMERIC FLAVIVIRUS LYSSAVIRUS VACCINES 국제(WO) | 공개 | 출원인 : KATHOLIEKE UNIVERSITEIT LEUVEN; | 출원번호 : EP2019/073897 ( 2019-09-06 ) | 공개번호 : 2020/049175 (2020-03-12) | IPC : A61K-039/12(2006.01); A61P-031/14(2006.01) The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region. 원문보기 초록 연관자료탐색 The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region. 5 [미국특허] PAN-LYSSAVIRUS VACCINES AGAINST RABIES 미국(US) | 공개 | 출원인 : The United States of America, as represented by the Secretary, Department of Health and Human Serv; | 출원번호 : US-0978135 ( 2015-12-22 ) | 공개번호 : US-0114026 (2016-04-28) | IPC : A61K-039/205(2006.01); C07K-014/005(2006.01); C12N-007/00(2006.01) Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. 대표청구항 원문보기 초록 연관자료탐색 Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. 6 [미국특허] Pan-lyssavirus vaccines against rabies 미국(US) | 등록 | 출원인 : The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention; | 출원번호 : US-0806622 ( 2011-06-23 ) | 특허번호 : US-9248179 (2016-02-02) | 등록번호 : US-9248179 (2016-02-02) | IPC : A61K-039/205(2006.01); A61K-039/12(2006.01); C07K-014/005(2006.01); C12N-007/00(2006.01); C12N-015/86(2006.01); A61K-039/00(2006.01) Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. 대표청구항 원문보기 초록 연관자료탐색 Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. 7 [미국특허] PAN-LYSSAVIRUS VACCINES AGAINST RABIES 미국(US) | 공개 | 출원인 : The Government of the United States of America as Represented by the Secretary of the Department of; | 출원번호 : US-0806622 ( 2011-06-23 ) | 공개번호 : US-0095137 (2013-04-18) | IPC : A61K-039/205(2006.01) Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. 대표청구항 원문보기 초록 연관자료탐색 Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies. 8 [유럽특허] LYSSAVIRUS ANTIGEN CONSTRUCTS 유럽(EP) | 공개 | 출원인 : GlaxoSmithKline Biologicals SA; | 출원번호 : 18759392.6 ( 2018-07-16 ) | 공개번호 : 3655536 (2020-05-27) | IPC : C12N-015/47(2006.01); C07K-014/145(2006.01); C12N-007/00(2006.01); C12N-015/86(2006.01); A61K-039/205(2006.01); A61K-039/00(2006.01) 원문보기 연관자료탐색 9 [미국특허] LYSSAVIRUS ANTIGEN CONSTRUCTS 미국(US) | 공개 | 출원인 : GLAXOSMITHKLINE BIOLOGICALS SA; | 출원번호 : 16630951 ( 2018-07-16 ) | 공개번호 : 20200222526 (2020-07-16) | IPC : A61K-039/205(2006.01); A61K-009/127(2006.01) Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity. 대표청구항 원문보기 초록 연관자료탐색 Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity. 10 [미국특허] LYSSAVIRUS ANTIGEN CONSTRUCTS 미국(US) | 공개 | 출원인 : GLAXOSMITHKLINE BIOLOGICALS SA; | 출원번호 : 17591421 ( 2022-02-02 ) | 공개번호 : 20220241398 (2022-08-04) | IPC : A61K-039/205(2006.01); A61K-009/127(2006.01) Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity. 대표청구항 원문보기 초록 연관자료탐색 Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.
AI-Helper 안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요. ※ AI-Helper는 부적절한 답변을 할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.